Skip to main content
Publications
Ahn M, Kang JH, Kim S, Kahangarie D, Nagar SP, Davis KL, Jimenez M, Seo M, Jung M, Sandelin M, Cho BC. Treatment (tx) patterns and outcomes in resectable early-stage NSCLC in South Korea: subgroup analysis of a global real-world (rw) study. Poster presented at the ESMO Asian Congress 2023; December 2, 2023. Singapore, China. [abstract] Ann Oncol. 2023; 34(Suppl 4):S1646-53.
Stattin P, Westerberg M, Franck Lissbrant I, Hjalm-Eriksson M, Kjellman A, Ullen A, Vassilev Z, Sandstrom P, Weinrib R, Martinez D, Garcia de Albeniz Martinez X. Real world outcomes in patients with metastatic, castration-resistant prostate cancer treated with radium-223 in routine clinical practice in Sweden. Clin Genitourin Cancer. 2022 Sep 9;S1558-7673(22):00194-X. doi: 10.1016/j.clgc.2022.09.002
Morris MJ, de Bono J, Nagarajah J, Wei XX, Nordquist T, Koshkin VS, Vickers A, Mirante O, Ghouse R, Tagawa S, Fizazi K. Radiographic progression‑free survival correlation with time‑to‑event endpoints: a post hoc analysis of the VISION trial. Poster presented at the 2022 ESMO Annual Congress; September 9, 2022. Paris, France. [abstract] Ann Oncol. 33(supplement 3):S1170-1. doi: 10.1016/j.annonc.2022.07.1506
Taylor MH, Leboulleux S, Panaseykin S, Konda B, de La Fouchardiere C, Hughes BGM, Gianoukakis AG, Park YJ, Romanov I, Krzyzanowska MK, Garbinsky D, Sherif B, Pan JJ, Binder TA, Sauter N, Xie R, Brose MS. Health-related quality-of-life (HRQoL) analyses from study 211: a phase 2 study in patients (pts) with radioiodine-refractory differentiated thyroid cancer (RR-DTC) treated with 2 starting doses of lenvatinib (LEN). Poster presented at the 46th Congress of European Society for Medical Oncology (ESMO); September 16, 2021. [abstract] Ann Oncol. 2021; 32(suppl_5):S1205-10. doi: 10.1016/annonc/annonc715
Anthony L, Ervin C, Lapuerta P, Kulke MH, Kunz P, Bergsland E, Horsch D, Metz DC, Pasieka J, Pavlakis N, Pavel M, Caplin M, Oberg K, Ramage J, Evans E, Yang QM, Jackson S, Arnold K, Law L, DiBenedetti DB. Understanding the patient experience with carcinoid syndrome: exit interviews from a randomized, placebo-controlled study of telotristat ethyl. Clin Ther. 2017 Nov 11;39(11):2158-68. doi: 10.1016/j.clinthera.2017.09.013
Casulo C, Day B, Dawson KL, Zhou X, Flowers CR, Farber CM, Hainsworth JD, Cerhan JR, Link BK, Zelenetz AD, Friedberg JW. Disease characteristics, treatment patterns, and outcomes of follicular lymphoma in patients 40 years of age and younger: an analysis from the National Lymphocare Study. Ann Oncol. 2015 Nov;26(11):2311-7. doi: 10.1093/annonc/mdv375
Fernandez-Martos C, Garcia-Albeniz X, Pericay C, Maurel J, Aparicio J, Montagut C, Safont MJ, Salud A, Vera R, Massuti B, Escudero P, Alonso V, Bosch C, Martin M, Minsky BD. Chemoradiation, surgery and adjuvant chemotherapy versus induction chemotherapy followed by chemoradiation and surgery: long-term results of the Spanish GCR-3 phase II randomized trial. Ann Oncol. 2015 Aug;26(8):1722-8. doi: 10.1093/annonc/mdv223
Barnes R, Earnshaw S, Herbrecht R, Morrissey O, Slavin M, Bow E, McDade C, Charbonneau C, Weinstein D, Kantecki M, Schlamm H, Maertens J. Economic comparison of an empirical versus diagnostic-driven strategy for treating invasive fungal disease in immunocompromised patients. Clin Ther. 2015 Jun 1;37(6):1317-28. doi: 10.1016/j.clinthera.2015.03.021
Danson S, Andreas S, Chouaid C, Siakpere O, Benjamin L, Ehness R, Dramard-Goasdoue M, Barth J, Price M, Wolowacz SE, Kaye JA, Kontoudis I. LuCaBIS: a burden of illness study in patients with stage IB-IIIA non-small cell lung cancer in France, Germany and the UK. Poster presented at ESMO (European Society for Medical Oncology) 2014 Congress; September 29, 2014. Madrid, Spain. [abstract] Ann Oncol. 2014 Sep 1; 25(Suppl 4):iv415-6. doi: 10.1093/annonc/mdu347
Mohr P, Harries M, Grange F, Ehness R, Benajmin L, Siakpere O, McLeod LD, Wolowacz SE, Kaye JA, Kontoudis I. Treatment patterns and disease burden of stage IIIB/IIIC melanoma in France, Germany and the UK. Poster presented at the ESMO 2014 Congress; September 28, 2014. Madrid, Spain. [abstract] Ann Oncol. 2014 Sep 1; 25(suppl 4):iv389. doi: 10.1093/annonc/mdu344.40
Nooka AK, Nabhan C, Zhou X, Taylor MD, Byrtek M, Miller TP, Friedberg JW, Zelenetz AD, Link BK, Cerhan JR, Sinha R, Shenoy PJ, Levy D, Dawson K, Hirata JH, Flowers CR. Examination of the follicular lymphoma international prognostic index (FLIPI) in the National LymphoCare study (NLCS): a prospective US patient cohort treated predominantly in community practices. Ann Oncol. 2013 Feb 1;24(2):441-8.
Zafar SY, Grothey A, Bekaii-Saab T, Bendell J, Sherrill B, Bennett L, Mun Y, Sersch M, Dalal D, Hurwitz HI. Survival among metastatic colorectal cancer (MCRC) patients treated in a randomized controlled trial (RCT) vs an observational cohort study (OCS). Poster presented at the 37th Annual Congress of the European Society for Medical Oncology; September 1, 2012. [abstract] Ann Oncol. 2012 Sep 1; 23(Suppl. 9):191.
Meltzer EO, Stahlman JE, Leflein J, Meltzer S, Lim J, Dalal AA, Prillaman BA, Philpot EE. Preferences of adult patients with allergic rhinitis for the sensory attributes of fluticasone furoate versus fluticasone propionate nasal sprays: a randomized, multicenter, double-blind, single-dose, crossover study. Clin Ther. 2008 Feb;30(2):271-9. doi: 10.1016/j.clinthera.2008.02.005
Richards DA, Boehm KA, Waterhouse DM, Wagener DJ, Krishnamurthi SS, Rosemurgy A, Grove W, Macdonald K, Gulyas S, Clark MJ, Dasse KD. Gemcitabine plus CI-994 offers no advantage over gemcitabine alone in the treatment of patients with advanced pancreatic cancer: results of a phase II randomized, double-blind, placebo-controlled, multicenter study. Ann Oncol. 2006 Jul 1;17:1096-102.